CyFlow CD99 PE
品番 | AT753952 | ||
---|---|---|---|
抗体名 | Anti-Hu CD99 PE,3B2/TA8 | ||
包装単位 | 100 tests | ||
濃度 | - | ||
容量 | 1 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG2a PE (BY503796) |
||
反応性|交差吸着 | Human | レーザー | Blue, Green, Yellow |
抗原 | CD99, MIC2, E2 | 最大蛍光波長 | 576 nm |
クローン | 3B2/TA8 | 最大励起波長 | 496 nm, 565 nm |
ホスト | Mouse | 標識/Format | PE |
アイソタイプ | IgG2a | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD99 PE,3B2/TA8
特異性
The mouse monoclonal antibody 3B2/TA8 recognizes CD99 antigen, a 32 kDa sialoglycoprotein expressed on many cell types, with particularly strong expression on Ewing´s sarcoma and peripheral primitive neuroectodermal tumors. Within the hematopoietic system, CD99 is expressed on virtually all cell types except granulocytes.
抗原情報
CD99 is a ubiquitous transmembrane type I sialoglycoprotein of a unique and poorly characterized protein family. CD99 is heavily O-glycosylated and was described as a T cell costimulator and strong activator of integrin-mediated actin cytoskeleton assembly, promoting cell adhesion and homotypic aggregation, immediate arrest on an inflamed vascular endothelium, and cell migration through it. Ligation of CD99 under some conditions can lead to apoptosis. Originally CD99 was described as a human thymus leukemia antigen, an Ewing´s sarcoma-specific membrane marker, and an adhesion molecule involved in spontaneous rosette formation of T cells with erythrocytes.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Brémond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, Breittmayer JP, Gounon P, Gleeson PA, Bernard A, Bernard G: Regulation of HLA class I surface expression requires CD99 and p230/golgin‑245 interaction. Blood. 2009·Jan·8; 113(2):347‑57. <·PMID:·18849489·>
• Kish DD, Gorbachev AV, Fairchild RL: CD8+ T cells produce IL‑2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses. J·Leukoc·Biol. 2005·Sep; 78(3):725‑35. <·PMID:·16000396·>
• Kueng HJ, Leb VM, Haiderer D, Raposo G, Thery C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF: General strategy for decoration of enveloped viruses with functionally active lipid‑modified cytokines. J·Virol. 2007·Aug; 81(16):8666‑76. <·PMID:·17537846·>
• Pickl WF, Pimentel-Muiños FX, Seed B: Lipid rafts and pseudotyping. J·Virol. 2001·Aug; 75(15):7175‑83. <·PMID:·11435598·>
• Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ, Baumruker T, Stöckl J, Ebner C, Knapp W, Pickl WF: CD99 engagement on human peripheral blood T cells results in TCR/CD3‑dependent cellular activation and allows for Th1‑restricted cytokine production. J·Immunol. 1998·Nov·1; 161(9):4671‑8. <·PMID:·9794396·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN